Nothing Special   »   [go: up one dir, main page]

CL2019002626A1 - Anticuerpos anti-par2 y usos de los mismos. - Google Patents

Anticuerpos anti-par2 y usos de los mismos.

Info

Publication number
CL2019002626A1
CL2019002626A1 CL2019002626A CL2019002626A CL2019002626A1 CL 2019002626 A1 CL2019002626 A1 CL 2019002626A1 CL 2019002626 A CL2019002626 A CL 2019002626A CL 2019002626 A CL2019002626 A CL 2019002626A CL 2019002626 A1 CL2019002626 A1 CL 2019002626A1
Authority
CL
Chile
Prior art keywords
par2
antibodies
antigen binding
binding fragments
par2 antibodies
Prior art date
Application number
CL2019002626A
Other languages
English (en)
Spanish (es)
Inventor
Claire Dobson
Richard Williams
Ian Gurrell
Sadhana Podichetty
David Fairman
Peter Thornton
Philip Newton
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CL2019002626A1 publication Critical patent/CL2019002626A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2019002626A 2017-03-16 2019-09-13 Anticuerpos anti-par2 y usos de los mismos. CL2019002626A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472462P 2017-03-16 2017-03-16
US201862637766P 2018-03-02 2018-03-02

Publications (1)

Publication Number Publication Date
CL2019002626A1 true CL2019002626A1 (es) 2019-12-06

Family

ID=61827709

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002626A CL2019002626A1 (es) 2017-03-16 2019-09-13 Anticuerpos anti-par2 y usos de los mismos.

Country Status (20)

Country Link
US (3) US10836822B2 (ja)
EP (1) EP3596125A1 (ja)
JP (2) JP7222901B2 (ja)
KR (1) KR102711884B1 (ja)
CN (1) CN110446720B (ja)
AU (2) AU2018235031B2 (ja)
BR (1) BR112019018752A2 (ja)
CA (1) CA3055251A1 (ja)
CL (1) CL2019002626A1 (ja)
CO (1) CO2019010975A2 (ja)
CR (1) CR20190417A (ja)
IL (1) IL269134B2 (ja)
MA (1) MA49886A (ja)
MX (1) MX2019010802A (ja)
NZ (1) NZ757915A (ja)
PH (1) PH12019502087A1 (ja)
SG (1) SG11201908056QA (ja)
TW (1) TWI788332B (ja)
UA (1) UA125757C2 (ja)
WO (1) WO2018167322A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102269708B1 (ko) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CN107973851A (zh) 2010-11-30 2018-05-01 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
KR102147548B1 (ko) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 FcγRIIb 특이적 Fc 항체
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
WO2016098357A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR101838645B1 (ko) 2014-12-19 2018-03-14 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
JP2018510842A (ja) 2015-02-05 2018-04-19 中外製薬株式会社 イオン濃度依存的抗原結合ドメインを含む抗体、Fc領域改変体、IL−8に結合する抗体、およびその使用
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
US11725052B2 (en) * 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024156720A1 (en) 2023-01-25 2024-08-02 Medimmune Limited Migraine therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2004080373A2 (en) * 2003-03-11 2004-09-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CA2586344C (en) * 2004-11-04 2013-05-28 New England Medical Center Hospitals, Inc. G protein coupled receptor agonists and antagonists and methods of use
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
AR070911A1 (es) * 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
KR102269708B1 (ko) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
JP2011530515A (ja) 2008-08-05 2011-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Par−2活性化のエフェクターおよび炎症の調節におけるその使用
JO3246B1 (ar) 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
EP2545079A2 (en) * 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
JP7037885B2 (ja) * 2014-06-30 2022-03-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング pH依存性抗原結合を示す抗TNFa抗体

Also Published As

Publication number Publication date
KR102711884B1 (ko) 2024-10-02
IL269134B2 (en) 2024-07-01
US20180305450A1 (en) 2018-10-25
AU2021257983A1 (en) 2021-11-25
TWI788332B (zh) 2023-01-01
CA3055251A1 (en) 2018-09-20
BR112019018752A2 (pt) 2020-05-05
CN110446720B (zh) 2023-09-12
US10836822B2 (en) 2020-11-17
SG11201908056QA (en) 2019-09-27
CO2019010975A2 (es) 2019-10-21
US20210061905A1 (en) 2021-03-04
KR20190129925A (ko) 2019-11-20
AU2018235031A1 (en) 2019-10-31
NZ757915A (en) 2023-05-26
MA49886A (fr) 2020-06-24
MX2019010802A (es) 2019-10-30
JP2023055895A (ja) 2023-04-18
TW201843176A (zh) 2018-12-16
JP7222901B2 (ja) 2023-02-15
US11591389B2 (en) 2023-02-28
IL269134B1 (en) 2024-03-01
JP2020509762A (ja) 2020-04-02
CR20190417A (es) 2019-12-06
IL269134A (en) 2019-11-28
UA125757C2 (uk) 2022-06-01
AU2018235031B2 (en) 2021-08-12
PH12019502087A1 (en) 2020-03-09
EP3596125A1 (en) 2020-01-22
US20230242639A1 (en) 2023-08-03
WO2018167322A1 (en) 2018-09-20
CN110446720A (zh) 2019-11-12

Similar Documents

Publication Publication Date Title
CL2019002626A1 (es) Anticuerpos anti-par2 y usos de los mismos.
CL2018003378A1 (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno.
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
AR114002A1 (es) Anticuerpos a lilrb2
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
AR106583A1 (es) Anticuerpos que se unen específicamente a pd-1, tim-3 o pd-1 y tim-3 y sus usos
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
EA201691650A1 (ru) Гидрофильные конъюгаты антитело-лекарственное средство
BR112016022841A2 (pt) cadeia j modificada
CO2017003005A2 (es) Anticuerpos anti-mfi2
BR112017001588A2 (pt) conjugados de anticorpo/fármaco anti-cdh6
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
BR112018010102A2 (pt) conjugados farmacêuticos de anticorpos sítio-específicos para her2
BR112017009813A2 (pt) conjugados de anticorpo fármaco
BR112017009764A2 (pt) anticorpos biespecíficos e métodos de uso em oftalmologia
ECSP17075750A (es) Neutralización del virus chikungunya mediada por anticuerpos
AR104604A1 (es) ANTICUERPOS ANTI-FcRn
ECSP19026593A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
DK3544637T3 (da) Native omv-antigenkonjugater og anvendelse deraf